USPTO serial 79440320
Serial No. 79440320
Reviewed by CopyMark Law Group
Status 645Office Action
- Filing date
- Status date
- Registration date
- —
- Examiner
- JOHNSON, DANYTHE ELIZABETH HA
- Law office
- TMO LAW OFFICE 120
What this means
The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.
Need help with Serial No. 79440320?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Office Action, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
R. Peter Spies
R. Peter Spies DTL, Ltd134 North LaSalle StSuite 1050Chicago, IL 60602Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Biochemicals, namely, monoclonal antibodies for in vitro scientific or research use; biomolecule labelling kits comprising reagents for use in scientific research; biochemicals namely, polypeptides for in vitro research use; diagnostic preparations for scientific or research use; reagents for scientific or medical research use; diagnostic preparations for research laboratory use; diagnostic reagents for scientific or research use; cell growth media for growing cells for use in scientific research; cell culture reagents for scientific and research use; stem cells for research or scientific purposes | ACTIVE | — |
| 009 | Scientific apparatus and instruments, namely, microfluidic in vitro systems and complex multi-cellular platforms for modeling neurobiological processes; apparatus for high-content imaging, optical and electrophysiological readouts for neuroscience drug discovery; computer software, recorded, for functional and morphological cell-based analytics and for analyzing data from high-content imaging, optical and electrophysiological readouts in the field of neuroscience drug discovery | ACTIVE | — |
| 041 | Publishing of texts in the nature of book publishing, reporting of texts in the nature of current event reporting, and writing of texts in the nature of writing of articles for professional journals other than for advertising or publicity; teaching in the field of neuroscience, pharmaceutical research, and drug discovery; arranging and conducting conferences and seminars in the field of neuroscience, pharmaceutical research, and drug discovery | ACTIVE | — |
| 042 | Scientific research and development; drug discovery services; development of pharmaceutical preparations and medicines; pharmaceutical drug development services; research on the subject of pharmaceuticals; conducting early evaluations in the field of new pharmaceuticals; consultancy in the field of pharmaceutical research; inspection of pharmaceuticals; laboratory research services relating to pharmaceuticals; pharmaceutical product evaluation; pharmaceutical research and development; biological research; biological analysis; biological product development services; biological laboratory services, namely, phenotypic and target-based assay development, assay validation, compound screening and lead optimization using advanced in vitro neuroscience platforms; biological research, clinical research in the field of neuroscience for modeling neurological and neurodegenerative diseases and medical research; medical and pharmacological research services; scientific research for medical purposes; research and development in the field of microorganisms and cells; chemical engineering; chemistry services, namely, compound screening and lead optimization for neuroscience drug discovery; clinical research in the field of neuroscience and neurodegenerative diseases; medical research laboratories; technological research in the field of biotechnology, functional genomics, and gene modulation; industrial analysis in the nature of safety and efficacy assessments for pharmaceutical research and industrial research services in the field of pharmaceutical and biotechnology research and development; blood analysis services for scientific research services; blood analysis services for scientific research purposes; biochemical research and development; pharmaceutical research and development for the pharmaceutical industry; research and development in the field of biotechnology; research and development in the pharmaceutical and biotechnology fields; provision of information and data relating to medical and veterinary research and development, namely, providing information and data relating to target discovery, target validation, and lead discovery in the field of neuroscience drug discovery; research and development services in the field of medical preparations; cell culture services for scientific and research purposes, for others | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 1, 2026 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jul 1, 2026 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jul 1, 2026 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| May 20, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 20, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 20, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 30, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Apr 10, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Apr 10, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 8, 2026 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 7, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 6, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 5, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jan 5, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 1, 2026 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |